News Releases

News Releases

Synteract Announces Participation in February/March Industry Events

RESEARCH TRIANGLE PARK, NC– February 11, 2019Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, is exhibiting at several upcoming industry trade shows this February and March. Experts from Synteract’s Centers for Development in dermatology, neuro degenerative, oncology, pediatrics, and rare and orphan diseases will be available to talk with drug developers about challenges in clinical trials.

Attendees can schedule an appointment with Synteract executives at:

Walter Boyle, executive director, Biostatistics and Programming at Synteract, will also speak on “Engagement & Analytics - Simple Path to Value for Your Data; or, How ‘Advanced’ Do Analytics Really Need to Be?” at OCT West Coast on Feb. 12 at 11 a.m. and again at OCT Southeast later in March.

As a full-service CRO – with operational and therapeutic expertise, relationships with top investigative sites, and advanced technology – Synteract specializes in helping drug developers to navigate the complexities of global Phase I - IV clinical trials. “Bringing Clinical Trials to Life” is the company’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. 

Individuals interested in meeting with a Synteract expert should contact Alberto Bryan at alberto.bryan@synteract.com to set up a meeting today.

About Synteract
With 800 employees across 21 countries, Synteract is an innovative CRO supporting biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, as well as pediatrics and rare and orphan.

Connect on LinkedIn and Twitter

# # #
CONTACT:
Hilary McCarthy
hilary@clearpointagency.com
508-829-2543

x

Submit RFI / RFP

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required